TONIX PHARMACEUTICALS HOLDING CORP (TNXP) — insider trading
Health Care · NASDAQ
TONIX PHARMACEUTICALS HOLDING CORP (TNXP) has 15 reported SEC Form 4 insider transactions in our data, including 6 open-market purchases among the most recent 15 (latest 2026-08-27).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-27 | LEDERMAN SETH | Director, Officer (Chief Executive Officer) | Open-market purchase | 2,000 | $13.79 | $27.6K | Form 4 |
| 2026-08-20 | BAGGER RICHARD H | Director | Open-market purchase | 1,000 | $12.60 | $12.6K | Form 4 |
| 2026-06-30 | SAENGER BRADLEY | Officer (Chief Financial Officer) | Other acquisition or disposition | 1,453 | $10.91 | $15.9K | Form 4 |
| 2026-06-12 | Taylor Carolyn E. | Director | Open-market purchase | 1,415 | $10.55 | $14.9K | Form 4 |
| 2026-06-09 | LEDERMAN SETH | Director, Officer (Chief Executive Officer) | Open-market purchase | 5,000 | $11.79 | $59.0K | Form 4 |
| 2026-06-08 | Stillwell Richard Newcomb | Director | Open-market purchase | 5,000 | $11.65 | $58.3K | Form 4 |
| 2026-05-12 | Taylor Carolyn E. | Director | Grant / award / vesting (derivative) | 22,700 | — | $0 | Form 4 |
| 2026-05-12 | BAGGER RICHARD H | Director | Grant / award / vesting (derivative) | 22,700 | — | $0 | Form 4 |
| 2026-05-12 | GRANGE DAVID L | Director | Grant / award / vesting (derivative) | 22,700 | — | $0 | Form 4 |
| 2026-05-12 | Treco James | Director | Grant / award / vesting (derivative) | 22,700 | — | $0 | Form 4 |
| 2026-05-12 | Hunter James Randolph Jr | Director | Grant / award / vesting (derivative) | 22,700 | — | $0 | Form 4 |
| 2026-05-12 | Bell Margaret Smith | Director | Grant / award / vesting (derivative) | 22,700 | — | $0 | Form 4 |
| 2026-05-12 | OLUKOTUN ADEOYE Y | Director | Grant / award / vesting (derivative) | 22,700 | — | $0 | Form 4 |
| 2026-05-12 | Stillwell Richard Newcomb | Director | Grant / award / vesting (derivative) | 22,700 | — | $0 | Form 4 |
| 2026-03-31 | LEDERMAN SETH | Director, Officer (Chief Executive Officer) | Open-market purchase | 5,000 | $12.62 | $63.1K | Form 4 |
Ask the chat about TNXP's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: TONIX PHARMACEUTICALS HOLDING CORP (TNXP).
Last updated 2026-08-27 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.